3 days Ago By Defense World Staff
Shares of Zimmer Biomet Holdings, Inc. ( NYSE:ZBH – Get Free Report ) have received a consensus recommendation of “Hold” from the twenty brokerages that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and six have given a buy rating to the company.
The average twelve-month target price among analysts that have covered the stock in the last year is $123.22. Several research analysts have issued reports on ZBH shares.
Robert W. Baird dropped their target price on shares of Zimmer Biomet from $155.00 to $145.
00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. JPMorgan Chase & Co. dropped their target price on shares of Zimmer Biomet from $125.
00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. Raymond James dropped their target price on shares of Zimmer Biomet from $128.
00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Wolfe Research started coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th.
They set a “peer perform” rating on the stock. Finally, Royal Bank of Canada increased their target price on shares of Zimmer Biomet from $120.00 to $125.
00 and gave the stock an “outperform” rating in a report on Monday, November 4th. Check Out Our Latest Research Report on ZBH Hedge Funds Weigh In On Zimmer Biomet Zimmer Biomet Trading Up 0.4 % ZBH stock opened at $113.
02 on Friday. The company has a market capitalization of $22.50 billion, a PE ratio of 21.
49, a P/E/G ratio of 2.07 and a beta of 1.02.
Zimmer Biomet has a 12 month low of $101.47 and a 12 month high of $133.90.
The firm’s 50-day moving average is $106.45 and its 200 day moving average is $109.94.
The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.
70. Zimmer Biomet ( NYSE:ZBH – Get Free Report ) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.
74 EPS for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.
82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a net margin of 14.
27% and a return on equity of 12.95%. The firm’s revenue was up 4.
1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.65 EPS.
On average, research analysts anticipate that Zimmer Biomet will post 7.99 EPS for the current year. Zimmer Biomet Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st.
Investors of record on Monday, September 30th were given a $0.24 dividend. This represents a $0.
96 annualized dividend and a dividend yield of 0.85%. The ex-dividend date was Monday, September 30th.
Zimmer Biomet’s payout ratio is currently 18.25%. About Zimmer Biomet ( Get Free Report Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide.
The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T.
products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. Featured Stories Five stocks we like better than Zimmer Biomet What are earnings reports? Is Monolithic Power Systems a Screaming Buy After Near 40% Drop? Industrial Products Stocks Investing Applied Materials Market Capitulates: Now is the Time to Buy What is Short Interest? How to Use It 3 Ultra-High Dividend Yield Stocks for the New Year Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter .
.
